The effect and safety of dulaglutide for hyperglycemia associated with R-CHOP thepapy

Phase 2

Recruiting

• Conditions: Malignant lymphoma; Malignant lymphoma, hyperglycemia; D008223

• Registration Number: JPRN-jRCT1031200022
• Lead Sponsor: Suyama Takuya

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

(1) Patients recieved R-CHOP therapy for malignant lymphoma
(2) ECOG performance status score 0-2
(3) Patients dignosed with Type2 diabetes, or Patients who have been found twice by repeated tests of either fasting blood glucose of 126 mg / dl or more and blood glucose of 200 mg / dl or more during first chemotherapy
(4) Patients who are not allergic to dulaglutide
(5) Patients who have never used duraglutide before
(6) Patients with written consent

Exclusion Criteria

(1) Patients with a history of hyperglycemic coma and diabetic ketoacidosis
(2) Patients with type 1 diabetes
(3) Patients judged by the researcher to be inappropriate as subjects

Study & Design

• Study Type: Interventional
• Study Design: Not specified